Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal.

Yawn BP, Suissa S, Rossi A.

NPJ Prim Care Respir Med. 2016 Sep 29;26:16068. doi: 10.1038/npjpcrm.2016.68. Review.

2.

Surfactant protein D, a clinical biomarker for chronic obstructive pulmonary disease with excellent discriminant values.

Akiki Z, Fakih D, Jounblat R, Chamat S, Waked M, Holmskov U, Sorensen GL, Nadif R, Salameh P.

Exp Ther Med. 2016 Mar;11(3):723-730. Epub 2016 Jan 13.

3.

Long-acting Inhaled Bronchodilator and Risk of Vascular Events in Patients With Chronic Obstructive Pulmonary Disease in Taiwan Population.

Tsai MJ, Chen CY, Huang YB, Chao HC, Yang CJ, Lin PJ, Tsai YH.

Medicine (Baltimore). 2015 Dec;94(51):e2306. doi: 10.1097/MD.0000000000002306. Erratum in: Medicine (Baltimore). 2016 Feb;95(8):e78fe.

4.

The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.

Papi A, Jones PW, Dalvi PS, McAulay K, McIver T, Dissanayake S.

Int J Chron Obstruct Pulmon Dis. 2015 Nov 9;10:2431-8. doi: 10.2147/COPD.S93375. eCollection 2015.

5.

Plasma Chemokine signature correlates with lung goblet cell hyperplasia in smokers with and without chronic obstructive pulmonary disease.

Kim V, Cornwell WD, Oros M, Durra H, Criner GJ, Rogers TJ.

BMC Pulm Med. 2015 Sep 30;15:111. doi: 10.1186/s12890-015-0103-2.

6.

Inhaled Pharmacotherapy and Stroke Risk in Patients with Chronic Obstructive Pulmonary Disease: A Nationwide Population Based Study Using Two-Stage Approach.

Lin HW, Chung CL, Lin YS, Yu CM, Lee CN, Bien MY.

PLoS One. 2015 Jul 9;10(7):e0130102. doi: 10.1371/journal.pone.0130102. eCollection 2015.

7.

The risk and outcomes of pneumonia in patients on inhaled corticosteroids.

Sibila O, Soto-Gomez N, Restrepo MI.

Pulm Pharmacol Ther. 2015 Jun;32:130-6. doi: 10.1016/j.pupt.2015.04.001. Epub 2015 May 5. Review.

8.

Anti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary disease.

Asai K, Kobayashi A, Makihara Y, Johnson M.

Int J Chron Obstruct Pulmon Dis. 2015 Apr 17;10:803-11. doi: 10.2147/COPD.S79842. eCollection 2015.

9.

Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD.

Gao J, Pleasants RA.

Int J Chron Obstruct Pulmon Dis. 2015 Apr 15;10:775-89. doi: 10.2147/COPD.S80656. eCollection 2015. Review.

10.

Regular inhaled corticosteroids in adult-onset asthma and the risk for future cancer: a population-based cohort study with proper person-time analysis.

Kok VC, Horng JT, Huang HK, Chao TM, Hong YF.

Ther Clin Risk Manag. 2015 Mar 26;11:489-99. doi: 10.2147/TCRM.S80793. eCollection 2015.

11.

Inflammatory markers and mortality among US adults with obstructive lung function.

Ford ES, Cunningham TJ, Mannino DM.

Respirology. 2015 May;20(4):587-93. doi: 10.1111/resp.12499. Epub 2015 Mar 4.

12.
13.

Factors influencing the measurement of plasma/serum surfactant protein D levels by ELISA.

Bratcher PE, Gaggar A.

PLoS One. 2014 Nov 3;9(11):e111466. doi: 10.1371/journal.pone.0111466. eCollection 2014.

14.
15.

Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.

Babu KS, Kastelik JA, Morjaria JB.

Br J Clin Pharmacol. 2014 Aug;78(2):282-300. doi: 10.1111/bcp.12334. Review.

16.
17.

Biomarkers in chronic obstructive pulmonary disease: confusing or useful?

Stockley RA.

Int J Chron Obstruct Pulmon Dis. 2014 Feb 7;9:163-77. doi: 10.2147/COPD.S42362. eCollection 2014. Review.

18.

Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study.

Festic E, Bansal V, Gajic O, Lee AS; United States Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators (USCIITG-LIPS)..

Mayo Clin Proc. 2014 Feb;89(2):154-62. doi: 10.1016/j.mayocp.2013.10.028.

19.

Budesonide/formoterol enhances the expression of pro Surfactant Protein-B in lungs of COPD patients.

Um SJ, Lam S, Coxson H, Man SF, Sin DD.

PLoS One. 2013 Dec 26;8(12):e83881. doi: 10.1371/journal.pone.0083881. eCollection 2013.

Supplemental Content

Support Center